Based on the above findings, we aimed to evaluate the potential benefits of the SGLT2 inhibitor dapagliflozin (Dap) on DKD in diabetic mice, focusing on its influence on reversing the SGK1‐mediated Th17/Treg cell imbalance. Here, SGK1 is linked to diabetic kidney disease.